ME01735B - Retard formulacija za pralnakasan - Google Patents
Retard formulacija za pralnakasanInfo
- Publication number
- ME01735B ME01735B MEP-2009-368A MEP36809A ME01735B ME 01735 B ME01735 B ME 01735B ME P36809 A MEP36809 A ME P36809A ME 01735 B ME01735 B ME 01735B
- Authority
- ME
- Montenegro
- Prior art keywords
- retard
- tablet
- drug
- layer
- tablet according
- Prior art date
Links
- CXAGHAZMQSCAKJ-WAHHBDPQSA-N (4s,7s)-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepine-4-carboxamide Chemical compound CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@H]1N(C(=O)[C@H](CCC2=O)NC(=O)C=3C4=CC=CC=C4C=CN=3)N2CCC1 CXAGHAZMQSCAKJ-WAHHBDPQSA-N 0.000 title abstract 3
- 229950000362 pralnacasan Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 2
- 201000004681 Psoriasis Diseases 0.000 claims abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract 2
- 201000008482 osteoarthritis Diseases 0.000 claims abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 2
- AUHBCNJHXCDLMK-UHFFFAOYSA-N diazepine-1-carboxamide Chemical compound NC(=O)N1C=CC=CC=N1 AUHBCNJHXCDLMK-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000011258 core-shell material Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000007939 sustained release tablet Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (8)
1. Retard tableta koja se sastoji od najmanje dva sloja, naznačena time što najmanje jedan sloj sadrži lek l S, 9S (RS, 3S) N-(2-etoksi-5-okso-tetrafuran-3-il)-6,10- diokso-9-(izohinolin-1-oil-amino)-l, 2, 3, 4, 7, 8, 9, l 0-oktahidro-6-H-piridazino [1, 2-a][1,2] diazepin-1-karboksamid i/ili njegove soli ili derivate i/ili njegove slobodne kiseline i brzo ga oslobađa i još najmanje jedan sloj koji sadrži lek l S, 9S (RS, 3S) N-(2-etoksi-5-okso-tetrafuran-3-il)-6,l 0-diokso-9-(izohinolin-1-oil amino)-1, 2, 3, 4, 7, 8, 9, 10-oktahidro-6-H-piridazino [1, 2-a][l,2] diazepin-1- karboksamid i/ili njegove soli ili derivate i/ili njegove slobodne kiseline i oslobađa ga usporeno.
2. Retard tableta prema patentnom zahtevu l, naznačena time što se tableta sastoje od dva sloja i ovi slojevi su slojevito raspoređeni ili u obliku jezgra i omotača.
3. Retard tableta prema jednom ili više patentnih zahteva l i 2, naznačena time što retard sloj čini jezgro u jezgro-omotač strukturi tablete.
4. Retard tableta prema jednom ili više patentnih zahteva l do 3, naznačena time što oba sloja sadrže najmanje jedan punioc, najmanje jedno vezivo i najmanje jedno klizno sredstvo.
5. Retard tableta prema jednom ili više patentnih zahteva l do 4, naznačena time što sloj koji brzo oslobađa lek dodatno sadrži najmanje jednu supstancu za razaranje sloja.
6. Retard tableta prema jednom ili više patentnih zahteva l do 4, naznačena time, što retard sloj sadrži najmanje jednu supstancu koja formira gel.
7. Retard tableta prema jednom ili više patentnih zahteva l do 6, naznačena time, što se najmanje 60 % leka oslobađa za najviše 30 minuta, a najmanje 90 % leka iz tablete se oslobodi posle 180 minuta.
8. Retard tableta prema jednom ili više patentnih zahteva l do 7, naznačena time, što se koristi za lečenje bolesti autoimunosti, dijabetesa tip I i tip Il, reumatskog artritisa, osteo - artritisa i/ili psorijaze. 9
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005048293A DE102005048293A1 (de) | 2005-10-08 | 2005-10-08 | Retardformulierung für Pralnacasan |
| PCT/EP2006/009466 WO2007042160A1 (de) | 2005-10-08 | 2006-09-29 | Retardformulierung für pralnacasan |
| EP06805947A EP1937221B1 (de) | 2005-10-08 | 2006-09-29 | Retardformulierung für pralnacasan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01735B true ME01735B (me) | 2010-08-31 |
Family
ID=37764039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2009-368A ME01735B (me) | 2005-10-08 | 2006-09-29 | Retard formulacija za pralnakasan |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8231904B2 (me) |
| EP (1) | EP1937221B1 (me) |
| JP (1) | JP2009511441A (me) |
| KR (1) | KR101362679B1 (me) |
| CN (1) | CN101277683B (me) |
| AT (1) | ATE422354T1 (me) |
| AU (1) | AU2006301573B2 (me) |
| BR (1) | BRPI0617184A2 (me) |
| CA (1) | CA2624838C (me) |
| CY (1) | CY1109131T1 (me) |
| DE (2) | DE102005048293A1 (me) |
| DK (1) | DK1937221T3 (me) |
| ES (1) | ES2322202T3 (me) |
| HR (1) | HRP20090254T1 (me) |
| IL (1) | IL190511A (me) |
| MA (1) | MA29803B1 (me) |
| ME (1) | ME01735B (me) |
| MY (1) | MY146552A (me) |
| NO (1) | NO339360B1 (me) |
| NZ (1) | NZ567268A (me) |
| PL (1) | PL1937221T3 (me) |
| PT (1) | PT1937221E (me) |
| RS (1) | RS50777B (me) |
| RU (1) | RU2419419C2 (me) |
| SI (1) | SI1937221T1 (me) |
| WO (1) | WO2007042160A1 (me) |
| ZA (1) | ZA200802031B (me) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107080846A (zh) | 2010-07-09 | 2017-08-22 | 詹姆斯.特林卡.格林 | 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统 |
| PH12013500172A1 (en) * | 2010-08-13 | 2022-10-24 | Euro Celtique Sa | Use of binders for manufacturing storage stable formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US5085865A (en) * | 1989-04-12 | 1992-02-04 | Warner-Lambert Company | Sustained release pharmaceutical preparations containing an analgesic and a decongestant |
| IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| CN1524526A (zh) * | 2003-03-02 | 2004-09-01 | 颖 王 | 尼群地平双层缓释制剂 |
| US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| CN1579401A (zh) * | 2003-08-11 | 2005-02-16 | 李亦武 | 一种止咳平喘药物新剂型及制备方法 |
| US7611728B2 (en) * | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
| WO2005048979A2 (en) * | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
| WO2005051350A2 (en) * | 2003-10-28 | 2005-06-09 | Torrent Pharmaceuticals Limited | Water dispersible tablet |
-
2005
- 2005-10-08 DE DE102005048293A patent/DE102005048293A1/de not_active Ceased
-
2006
- 2006-09-29 MY MYPI20080752A patent/MY146552A/en unknown
- 2006-09-29 NZ NZ567268A patent/NZ567268A/en not_active IP Right Cessation
- 2006-09-29 AU AU2006301573A patent/AU2006301573B2/en not_active Ceased
- 2006-09-29 JP JP2008533913A patent/JP2009511441A/ja active Pending
- 2006-09-29 KR KR1020087008466A patent/KR101362679B1/ko not_active Expired - Fee Related
- 2006-09-29 HR HR20090254T patent/HRP20090254T1/xx unknown
- 2006-09-29 CN CN2006800369452A patent/CN101277683B/zh not_active Expired - Fee Related
- 2006-09-29 DK DK06805947T patent/DK1937221T3/da active
- 2006-09-29 PT PT06805947T patent/PT1937221E/pt unknown
- 2006-09-29 SI SI200630266T patent/SI1937221T1/sl unknown
- 2006-09-29 RU RU2008113381/15A patent/RU2419419C2/ru not_active IP Right Cessation
- 2006-09-29 ME MEP-2009-368A patent/ME01735B/me unknown
- 2006-09-29 RS RSP-2009/0174A patent/RS50777B/sr unknown
- 2006-09-29 ES ES06805947T patent/ES2322202T3/es active Active
- 2006-09-29 BR BRPI0617184-2A patent/BRPI0617184A2/pt not_active IP Right Cessation
- 2006-09-29 PL PL06805947T patent/PL1937221T3/pl unknown
- 2006-09-29 EP EP06805947A patent/EP1937221B1/de active Active
- 2006-09-29 CA CA2624838A patent/CA2624838C/en not_active Expired - Fee Related
- 2006-09-29 AT AT06805947T patent/ATE422354T1/de active
- 2006-09-29 WO PCT/EP2006/009466 patent/WO2007042160A1/de not_active Ceased
- 2006-09-29 DE DE502006002851T patent/DE502006002851D1/de active Active
-
2008
- 2008-03-04 ZA ZA200802031A patent/ZA200802031B/xx unknown
- 2008-03-24 MA MA30779A patent/MA29803B1/fr unknown
- 2008-03-30 IL IL190511A patent/IL190511A/en not_active IP Right Cessation
- 2008-04-04 US US12/062,683 patent/US8231904B2/en not_active Expired - Fee Related
- 2008-04-21 NO NO20081896A patent/NO339360B1/no not_active IP Right Cessation
-
2009
- 2009-04-23 CY CY20091100457T patent/CY1109131T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115005T1 (el) | Φαρμακευτικο σκευασμα ανθεκτικο στην καταχρηση | |
| WO2006105173A3 (en) | Oral delivery vehicle and material | |
| MX336861B (es) | Formulacion de farmaco resistente al abuso. | |
| CY1115825T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους | |
| MX395710B (es) | Composiciones gomosas de multicomponentes con nucleo duro. | |
| EA200900211A1 (ru) | Замещенные производные имидазолона, их получение и применение | |
| UY30373A1 (es) | Derivados de fenilalanina, procedimientos de preparacion y aplicaciones | |
| Parthsarathy et al. | Boarfish (Capros aper) protein hydrolysate has potent insulinotropic and GLP-1 secretory activity in vitro and acute glucose lowering effects in mice | |
| JP2014218522A5 (me) | ||
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| UA101903C2 (ru) | Лекарственное средство на основе дииндолилметана для лечения гиперпластических и воспалительных заболеваний | |
| BRPI0418681A (pt) | um suplemento dietético para o tratamento e a prevenção de doenças do sistema digestivo e doenças relacionadas ao sistema digestivo e método de produção e administração deste | |
| BR112015008284A2 (pt) | processo para preparar uma formulação farmacêutica particulada de gosto mascarado | |
| HRP20170734T1 (hr) | Povećana biodostupnost lijeka u terapiji naltreksonom | |
| BR112013003573A2 (pt) | comprimido de mesalazina tendo dissolução melhorada conforme antecedentes da invenção | |
| TR201906158T4 (tr) | Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar. | |
| DE502007002949D1 (de) | Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel | |
| GB2443793B (en) | Product, method of manufacture and use | |
| NO20082848L (no) | Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre | |
| WO2007075255B1 (en) | Mastic gum composition for use as a dietary supplement in humans and animals | |
| WO2020060779A3 (en) | Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle | |
| ITFI20050041A1 (it) | Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono | |
| WO2005079750A3 (en) | Films for use as dosage forms | |
| JP2017001966A5 (me) | ||
| RU2008113381A (ru) | Композиция пролонгированного высвобождения для пралнакасана |